基本信息
views: 353
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
In my research group, we focus on stimulating cardiac regeneration, thereby using approaches that can lead to improved recovery of cardiac tissue upon injury and improve the diagnosis of acute myocardial damage. In recent years, we identified miRNAs that can push cell lineage specifications and how we could improve progenitor cell transplantation, specifically improving local delivery and cell retentions. This was in close collaborations with Domian (Harvard), Sussman (San Diego State University), and Mercola (Sanford Burnham Medical Research Institute). My group substantially improved cell delivery to the myocardium, from which we also realized that most of the injected cell action was due to the potential paracrine actions. My group has therefore started to study the use of secreted exosomes by these cells as a novel approach to induce cardiac repair and aim to create a potential of-the-shelf therapy.
We have also identified several microRNAs that could be used as a direct therapeutic after myocardial damage has occured. Among them, miR-100 (Circulation 2011) and miR-214 for angiogenesis (CardioVascRes 2012), and miR-25 for heart failure (Nature 2014). These potent targets need smart delivery strategies to prevent side-effects; this directly lead me to initiate the BMM-LUST program that uses nano-medicine for targeted delivery. BMM-LUST made use of polymer-based delivery routes; the next leap in targeted delivery, I believe, lies in a natural carrier system. At this stage these polymer-based delivery routes are easily outperformed by the natural carrier system that transport biologicals between cells, called exosomes. I therefore propose the EVICARE program to combine my expertise in cardiac cell therapy, microRNA therapeutics and the use of our newly developed matrices for local delivery. My enthusiasm for introducing innovative molecular approaches and new therapeutic strategies, and my wide experiences in progenitor cell biology and preclinical animal model testing for cardiac injury will ensure that this research can go quickly from basic discoveries to preclinical testing in patient relevant animal models.
Research Interests
Papers共 402 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
I.R. Kelters, J.S. van der Geest, V. Sampaio-Pinto, P.M. Zwetsloot, A.J. Teske,T.P. De Boer,N.P. van der Kaaij,J.P. Sluijter,L.W. Van Laake
M C I Labonia, M Estapé Senti, P H van der Kraak,M A D Brans, I Dokter, T J Streef, A M Smits,A K Deshantri,S C A de Jager,R M Schiffelers,J P G Sluijter,P Vader
Journal of controlled release : official journal of the Controlled Release Society (2024): 734-745
JHLT Open (2024): 100042
Yihua Bei,Yujiao Zhu, Jingwen Zhou,Songwei Ai,Jianhua Yao,Mingming Yin,Meiyu Hu, Weitong Qi,Michail Spanos,Lin Li,Meng Wei,Zhenzhen Huang,
Circulation (2024)
Cardiovascular Researchno. Supplement_1 (2024)
M.T. Vervoorn, A.S. Scheren, S. Van Tuijl, E.M. Ballan, P.H. Van der Kraak,S.E. Kaffka Genaamd Dengler, S.C. De Jager, R. Goldschmeding,A. Vink,J.P. Sluijter,P.A. Doevendans,L.W. Van Laake,
The Journal of Heart and Lung Transplantationno. 4 (2024): S247
Simonides Immanuel van de Wakker,Julia Bauza-Martinez, Carla Rios Arceo, Herak Manjikian, Christian Jamie Bernard Snijders Blok, Marieke Theodora Roefs,Eduard Willms,Renee Goverdina Catharina Maas,Matti Feije Pronker,Olivier Gerrit de Jong,Wei Wu,Andre Goergens,
JOURNAL OF EXTRACELLULAR VESICLESno. 1 (2024): e12396-e12396
V Sampaio-Pinto, I R Kelters,J S A Van Der Geest,P P Zwetsloot, A J Teske,T P De Boer,N P Van Der Kaaij,J P G Sluijter,L W Van Laake
Cardiovascular Researchno. Supplement_1 (2024)
Journal of Extracellular Vesiclesno. 1 (2024): e12389-e12389
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn